Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Article in British Journal of Cancer (June 2024)
The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.
Article in British Journal of Cancer (June 2024)
Preprint in bioRxiv (January 2024)
Book chapter (January 2024)